Abstract

Histological stratification in metastatic non-small cell lung cancer (NSCLC) is essential to properly guide therapy. Morphological evaluation remains the basis for subtyping and is completed by additional immunohistochemistry labelling to confirm the diagnosis, which delays molecular analysis and utilises precious sample. Therefore, we tested the capacity of convolutional neural networks (CNNs) to classify NSCLC based on pathologic HES diagnostic biopsies. The model was estimated with a learning cohort of 132 NSCLC patients and validated on an external validation cohort of 65 NSCLC patients. Based on image patches, a CNN using InceptionV3 architecture was trained and optimized to classify NSCLC between squamous and non-squamous subtypes. Accuracies of 0.99, 0.87, 0.85, 0.85 was reached in the training, validation and test sets and in the external validation cohort. At the patient level, the CNN model showed a capacity to predict the tumour histology with accuracy of 0.73 and 0.78 in the learning and external validation cohorts respectively. Selecting tumour area using virtual tissue micro-array improved prediction, with accuracy of 0.82 in the external validation cohort. This study underlines the capacity of CNN to predict NSCLC subtype with good accuracy and to be applied to small pathologic samples without annotation.

Details

Title
Using a convolutional neural network for classification of squamous and non-squamous non-small cell lung cancer based on diagnostic histopathology HES images
Author
Le Page Anne Laure 1 ; Ballot Elise 2 ; Truntzer Caroline 3 ; Derangère Valentin 4 ; Ilie Alis 5 ; Rageot, David 6 ; Bibeau, Frederic 1 ; Ghiringhelli Francois 7 

 Normandy University, Department of Pathology, Caen University Hospital, Caen, France (GRID:grid.460771.3) (ISNI:0000 0004 1785 9671) 
 Georges François Leclerc Cancer Center—UNICANCER, Platform of Transfer in Biological Oncology, Dijon, France (GRID:grid.460771.3) 
 Georges François Leclerc Cancer Center—UNICANCER, Platform of Transfer in Biological Oncology, Dijon, France (GRID:grid.460771.3); Dijon University Hospital, Genomic and Immunotherapy Medical Institute, Dijon, France (GRID:grid.31151.37) 
 Georges François Leclerc Cancer Center—UNICANCER, Platform of Transfer in Biological Oncology, Dijon, France (GRID:grid.31151.37); Dijon University Hospital, Genomic and Immunotherapy Medical Institute, Dijon, France (GRID:grid.31151.37); University of Burgundy-Franche Comté, Dijon, France (GRID:grid.5613.1) (ISNI:0000 0001 2298 9313); UMR INSERM 1231, Dijon, France (GRID:grid.5613.1) 
 Georges François Leclerc Cancer Center—UNICANCER, Platform of Transfer in Biological Oncology, Dijon, France (GRID:grid.5613.1) 
 Georges François Leclerc Cancer Center—UNICANCER, Platform of Transfer in Biological Oncology, Dijon, France (GRID:grid.5613.1); University of Burgundy-Franche Comté, Dijon, France (GRID:grid.5613.1) (ISNI:0000 0001 2298 9313) 
 Georges François Leclerc Cancer Center—UNICANCER, Platform of Transfer in Biological Oncology, Dijon, France (GRID:grid.460771.3); Dijon University Hospital, Genomic and Immunotherapy Medical Institute, Dijon, France (GRID:grid.31151.37); University of Burgundy-Franche Comté, Dijon, France (GRID:grid.5613.1) (ISNI:0000 0001 2298 9313); UMR INSERM 1231, Dijon, France (GRID:grid.5613.1); Georges François Leclerc Cancer Center—UNICANCER, Department of Medical Oncology, Dijon, France (GRID:grid.5613.1) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2609525239
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.